Related Experiment Video
Updated: Mar 26, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Persistent Hypoglycemia in Patient with Hodgkin's Disease
Harold Cinco Lim1, Lubna Bashir Munshi1, David Sharon2
1Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
Case Reports in Oncological Medicine
|February 4, 2016
Summary
Hypoglycemia, a rare complication of Hodgkin's disease, can be challenging to manage. This case study suggests prednisone may effectively treat hypoglycemia associated with lymphoma.
Area of Science:
- Oncology
- Endocrinology
- Internal Medicine
Background:
- Hypoglycemia is an uncommon complication of Hodgkin's disease.
- The precise pathophysiology of hypoglycemia in Hodgkin's disease remains unclear.
- This report details a patient with newly diagnosed Stage IV Hodgkin's disease experiencing persistent hypoglycemia.
Purpose of the Study:
- To present a unique case of hypoglycemia in Hodgkin's disease.
- To explore potential treatment strategies for lymphoma-associated hypoglycemia.
- To contribute to understanding the pathophysiology of this rare complication.
Main Methods:
- Case report of a patient with Stage IV Hodgkin's disease.
- Administration of standard hypoglycemia treatments (glucagon, dextrose infusions).
- Diagnostic workup including C-peptide levels.
- Therapeutic trial of prednisone for hypoglycemia management.
Main Results:
- The patient presented with persistent and recurrent hypoglycemia unresponsive to conventional treatments.
- Low C-peptide levels suggested non-insulin-dependent hypoglycemia.
- Prednisone administration successfully resolved hypoglycemic episodes, maintaining euglycemia.
- A substance mimicking insulin's effects was suspected, potentially secreted by lymphoma cells.
Conclusions:
- Prednisone may be an effective treatment for hypoglycemia in Hodgkin's disease patients.
- The findings support the hypothesis of tumor-secreted factors causing hypoglycemia.
- Further research is needed to elucidate the exact mechanisms of hypoglycemia in Hodgkin's disease.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
929
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
929
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
845
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
01:22Diabetes Mellitus: Overview and Type I Subtype
5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K